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INTRODUCTION
Public health officials rely on health providers, laboratories, and other public health
personnel to report the occurrence of notifiable diseases to state and local health
departments. Without such data, monitoring trends or evaluating the effectiveness of
intervention activities would be difficult.
The Council of State and Territorial Epidemiologists (CSTE) has recommended that
state health departments report cases of selected diseases (Table 1) to CDC’s National
Notifiable Diseases Surveillance System (NNDSS). However, the usefulness of such
data has been limited by the lack of uniform case definitions for public health surveil-
lance (1 ). Without explicit criteria for identifying cases, state health departments and
individual practitioners have used various criteria for case reporting. This document,
prepared in cooperation with the CSTE, provides uniform criteria for reporting pur-
poses. States that wish to improve the specificity of reporting may find the definitions
helpful. As uniform case definitions are adopted, the incidence of reported diseases in
different geographic areas may be more meaningfully compared.
In the United States, requirements for reporting diseases are mandated by state
laws or regulations, and the list of reportable diseases in each state varies. A summary
of state requirements for notifiable diseases has recently been published (2 ). National
data from the NNDSS are collated and published weekly in the Morbidity and Mortal-
ity Weekly Report (MMWR). In general, cases reported by state health departments to
the NNDSS are provisional. Updated final reports are published annually in the Sum-
mary of Notifiable Diseases.
Additionally, state health departments provide CDC information about these and
other conditions of public health interest through supplementary surveillance systems
that collect more detailed, condition-specific information (3 ). These conditions may or
may not be included in the state laws or regulations that mandate reporting (Table 2).
The CSTE/CDC surveillance case definitions included in this document vary in their
use of clinical, laboratory, and epidemiologic criteria to define cases. Some clinical
1
Centers for Disease Control
2
Council of State and Territorial Epidemiologists
The authors were assisted by Joel R. Greenspan, M.D., M.P.H., Stephen L. Cochi, M.D., Steven
L. Solomon, M.D., Joseph E. Sniezek, M.D., M.P.H., Alan B. Bloch, M.D., M.P.H., Steven M.
Teutsch, M.D., M.P.H., and the Council of State and Territorial Epidemiologists.
Vol. 39 / No. RR-13 MMWR 1
TABLE 1. Diseases included in the National Notifiable Diseases Surveillance System
(NNDSS)











Congenital rubella syndrome Rocky Mountain spotted fever
Diphtheria Rubella
Encephalitis, post chickenpox Salmonellosis
Encephalitis, post mumps Shigellosis
Encephalitis, post other Syphilis, all stages
Encephalitis, primary Syphilis, primary and secondary
Gonorrhea Syphilis, congenital
Granuloma inguinale Tetanus
Hansen disease Toxic shock syndrome
Hepatitis A Trichinosis
Hepatitis B Tuberculosis
Hepatitis, non-A, non-B Tularemia





*Many states collect case reports of varicella, although it is not a nationally notifiable disease.
The Council of State and Territorial Epidemiologists encourages transmission of that informa-
tion annually via the NNDSS for publication in the Summary of Notifiable Diseases.
TABLE 2. Diseases and Conditions that are not nationally notifiable but for which
CDC maintains surveillance*





Dengue fever Mucopurulent cervicitis
Genital herpes simplex virus infection Nongonococcal urethritis
Genital warts Pelvic inflammatory disease
Giardiasis Reye syndrome
Haemophilus influenzae, invasive disease Spinal cord injury
*This list includes only the diseases and conditions for which case definitions are provided in
this document; it is not a complete list of non-notifiable diseases for which CDC and state and
territorial health departments maintain surveillance systems.
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syndromes do not have confirmatory laboratory tests, but laboratory evidence may be
one component of a clinical definition; toxic shock syndrome is an example. Other
diseases (e.g., mumps) have such a characteristic clinical presentation that, even in
the absence of confirmatory laboratory testing, a diagnosis may be based only on
clinical findings. In most instances, a brief clinical description is provided. Unless the
clinical description is explicitly cited in the “Case classification” section of each defini-
tion, it is included only as background information.
Some diseases require laboratory confirmation for diagnosis, regardless of clinical
symptomatology, and some are diagnosed on the basis of epidemiologic data. Many
of the childhood vaccine-preventable diseases include epidemiologic criteria (e.g.,
exposure to probable or confirmed cases of disease) in the case definitions. In some
instances, the site of infection may be important; pharyngeal diphtheria is notifiable,
for example, whereas cutaneous diphtheria is not.
For many diseases, substantial amounts of information, including results of labora-
tory tests, must be collected before a final case classification is possible. State health
departments are requested to continue reporting provisional cases to the NNDSS
promptly, and records should be updated when additional surveillance information
becomes available.
Surveillance demands uniformity, simplicity, and brevity. These case definitions are
intended to establish uniform criteria for disease reporting; they should not be used as
sole criteria for establishing clinical diagnoses, determining the standard of care
necessary for a particular patient, setting guidelines for quality assurance, providing
standards for reimbursement, or initiating public health actions. Use of additional
clinical, epidemiologic, and laboratory data may enable a physician to diagnose a
disease even though the surveillance case definition may not be met. For example, an
adolescent with bilateral orchitis who attends a school in which a mumps outbreak is
occurring would not meet the surveillance case definition for mumps unless the
mumps virus was isolated. However, clinical judgment would suggest that in this situ-
ation, viral isolation is not necessary.
As knowledge increases and diagnostic technology improves, some definitions will
change to reflect those trends. For example, many cases of non-A, non-B hepatitis are
due to the recently described hepatitis C virus (4 ). Therefore, revisions, additions, and
deletions can be expected in the future.
DEFINITION OF TERMS USED IN CASE CLASSIFICATION
Confirmed case: a case that is classified as confirmed for reporting purposes.
Probable case: a case that is classified as probable for reporting purposes.
Laboratory-confirmed case: a case that is confirmed by one or more of the labora-
tory methods listed in the case definition under “Laboratory criteria for diagnosis.”
Although other laboratory methods may be used in clinical diagnosis, only those
listed are accepted for laboratory confirmation for reporting purposes.
 Clinically compatible case: a clinical syndrome generally compatible with the dis-
ease, but no specific clinical criteria need to be met unless they are noted in the case
classification.
Supportive laboratory results: specified laboratory results consistent with the diag-
nosis but not meeting the criteria for laboratory confirmation.
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Epidemiologically linked case: a case in which the patient has/has had contact with
one or more persons who have/had the disease, and transmission of the agent by the
usual modes of transmission is plausible. A case may be considered epidemiologi-
cally linked to a laboratory-confirmed case if at least one case in the chain of
transmission is laboratory confirmed.
Meets the clinical case definition: meets precisely the clinical case definition. Al-
though in clinical practice the diagnosis may be made with the use of other criteria, for
reporting purposes the stated criteria must be met.
CASE DEFINITIONS
Acquired Immunodeficiency Syndrome (AIDS)
Surveillance case definitions for acquired immunodeficiency syndrome (AIDS) and
human immunodeficiency virus (HIV) infection have been previously published in:
CDC. Revision of the CDC surveillance case definition for acquired immunodefi-
ciency syndrome. MMWR 1987;36(no. 1S).
Case classification systems have also been published in:
CDC. Classification system for human T-lymphotropic virus type III/
lymphadenopathy-associated virus infections. MMWR 1986;35:334-9.
CDC. Classification system for human immunodeficiency virus (HIV) infection in
children under 13 years of age. MMWR 1987;36:225-30,235.
Amebiasis
Clinical description
Infection of the large intestine by Entamoeba histolytica  may result in an illness of
variable severity, ranging from mild, chronic diarrhea to fulminant dysentery. Infec-
tion may also be asymptomatic.
Extraintestinal infection may also occur. The most common is hepatic abscess.
Laboratory criteria for diagnosis
Intestinal amebiasis
• Demonstration of cysts or trophozoites of E. histolytica  in stool, or
• Demonstration of trophozoites in tissue biopsy or ulcer scrapings by culture or
histopathology
Extraintestinal amebiasis
• Demonstration of E. histolytica  trophozoites in extraintestinal tissue
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Case classification
Confirmed, intestinal amebiasis: a clinically compatible illness that is laboratory
confirmed
Confirmed, extraintestinal amebiasis: a parasitologically confirmed infection
of extraintestinal tissue; or among symptomatic persons with clinical and/or
radiographic findings consistent with extraintestinal infection, demonstration of
specific antibody against E. histolytica, as measured by indirect hemagglutination
(IHA) or other reliable immunodiagnostic test such as enzyme-linked immunosor-
bent assay (ELISA).
Comment
Asymptomatic intestinal carriage of E. histolytica  should not be reported. Among




An illness with acute onset characterized by several distinct clinical forms
including:
• Cutaneous (a skin lesion evolving over 2 to 6 days from a papule, through a ve-
sicular stage, to a depressed black eschar)
• Inhalation (a brief prodrome resembling a viral respiratory illness followed by
development of hypoxia and dyspnea, with x-ray evidence of mediastinal
widening)
• Intestinal (severe abdominal distress followed by fever and signs of septicemia)
• Oropharyngeal (mucosal lesion in the oral cavity or oropharynx, cervical ade-
nopathy and edema, and fever)
Laboratory criteria for diagnosis
• Isolation of Bacillus anthracis  from a clinical specimen, or
• Fourfold or greater rise in either the anthrax enzyme-linked immunosorbent as-
say (ELISA) or electrophoretic immunotransblot (EITB) titer between acute- and
convalescent-phase serum specimens obtained ≥2 weeks apart, or
• Anthrax ELISA titer ≥64 or an EITB reaction to the protective antigen and/or lethal
factor bands in one or more serum samples obtained after onset of symptoms, or
• Demonstration of B. anthracis  in a clinical specimen by immunofluorescence
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Case classification
Confirmed: a clinically compatible illness that is laboratory confirmed
Aseptic Meningitis
Clinical description
A syndrome characterized by acute onset of meningeal symptoms, fever, and cere-
brospinal fluid pleocytosis, with bacteriologically sterile cultures. (See Encephalitis,
Arboviral.)
Laboratory criteria for diagnosis
• No evidence of bacterial or fungal meningitis
Case classification
Confirmed: a clinically compatible illness diagnosed by a physician as aseptic men-
ingitis, with no laboratory evidence of bacterial or fungal meningitis
Comment
Aseptic meningitis is a syndrome of multiple etiologies, but many cases are caused
by a viral agent.
Botulism, Foodborne
Clinical description
Ingestion of botulinal toxin results in an illness of variable severity. Common symp-
toms are diplopia, blurred vision, and bulbar weakness. Symmetric paralysis may
progress rapidly. (See CDC Botulism Manual.)
Laboratory criteria for diagnosis
• Detection of botulinal toxin in serum, stool, or patient’s food, or
• Isolation of Clostridium botulinum  from stool
Case classification
Confirmed: a clinically compatible illness that is laboratory confirmed or that oc-
curs among persons who ate the same food as persons with laboratory-confirmed
botulism
Comment
Botulism may be diagnosed without laboratory confirmation if the clinical and
epidemiologic evidence is overwhelming.
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Botulism, Infant
Clinical description
An illness of infants, characterized by constipation, poor feeding, and “failure to
thrive” that may be followed by progressive weakness, impaired respiration, and
death. (See CDC Botulism Manual.)
Laboratory criteria for diagnosis
• Detection of botulinal toxin in stool, or
• Isolation of Clostridium botulinum  from stool
Case classification
Confirmed: a clinically compatible, laboratory-confirmed illness occurring among
children <1 year of age
Botulism, Wound
Clinical description
An illness resulting from toxin produced by Clostridium botulinum  that has in-
fected a wound. (See CDC Botulism Manual.)
Laboratory criteria for diagnosis
• Detection of botulinal toxin in serum, or
• Isolation of Clostridium botulinum  from wound
Case classification
Confirmed: a clinically compatible illness that is laboratory confirmed among pa-
tients with no suspect food exposure and with a history of a fresh, contaminated




Laboratory criteria for diagnosis
• Detection of botulinal toxin in clinical specimen, or
• Isolation of Clostridium botulinum  from clinical specimen
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Case classification
Confirmed: an illness clinically compatible with botulism that is laboratory con-
firmed among patients >11 months of age, without histories of ingestion of suspect
food, and without wounds
Brucellosis
Clinical description
An illness characterized by acute or insidious onset of fever, night sweats, undue
fatigue, anorexia, weight loss, headache, and arthralgia
Laboratory criteria for diagnosis
• Isolation of Brucella  sp. from a clinical specimen, or
• Fourfold or greater rise in Brucella  agglutination titer between acute- and
convalescent-phase serum specimens obtained ≥2 weeks apart and studied at
the same laboratory, or
• Demonstration of Brucella  sp. in a clinical specimen by immunofluorescence
Case classification
Probable: a clinically compatible case that is epidemiologically linked to a con-
firmed case or that has supportive serology (i.e., Brucella  agglutination titer of
≥160 in one or more serum specimens obtained after onset of symptoms)
Confirmed: a clinically compatible illness that is laboratory confirmed
Campylobacter  Infection
Clinical description
Infection that may result in diarrheal illness of variable severity
Laboratory criteria for diagnosis
• Isolation of Campylobacter  from any clinical specimen
Case classification
Probable: a clinically compatible illness that is epidemiologically linked to a con-
firmed case
Confirmed: a case that is laboratory confirmed
Comment
Only confirmed cases are reported to the laboratory-based surveillance system
operated by the Enteric Diseases Branch, Center for Infectious Diseases, CDC.
States collecting data on Campylobacter  infection may wish to collect reports of
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A sexually transmitted disease characterized by painful genital ulceration and
inflammatory inguinal adenopathy. The disease is caused by infection with Haemo-
philus ducreyi.
Laboratory criteria for diagnosis
• Isolation of H. ducreyi  from a clinical specimen
Case classification
Probable: a clinically compatible case with one or more painful genital ulcers and
both a) no evidence of Treponema pallidum  infection by darkfield examination of
ulcer exudate or by a serologic test for syphilis performed at least 7 days after onset
of ulcers, and b) the clinical presentation of the ulcer(s) is not typical of disease
caused by herpes simplex virus (HSV), or HSV culture is negative
Confirmed: a case that is laboratory confirmed
Chlamydia trachomatis  Infection
Clinical description
Infection with Chlamydia trachomatis  may result in urethritis, epididymitis, cervici-
tis, acute salpingitis, or other syndromes when sexually transmitted. Perinatal
infections may result in inclusion conjunctivitis and pneumonia among newborns.
Other syndromes caused by C. trachomatis  include lymphogranuloma venereum
(see Lymphogranuloma Venereum Infection) and trachoma.
Laboratory criteria for diagnosis
• Isolation of C. trachomatis  by culture, or
• Demonstration of C. trachomatis  in a clinical specimen by antigen detection
methods
Case classification
Confirmed: a case that is laboratory confirmed
Cholera
Clinical description
An illness characterized by diarrhea and/or vomiting. Severity is variable.
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Laboratory criteria for diagnosis
• Isolation of toxigenic (cholera toxin-producing) Vibrio cholerae  01 from stool or
vomitus, or
• Significant rise in vibriocidal or antitoxic antibodies in acute- and early convales-
cent-phase sera, or
• Significant fall in vibriocidal antibodies in early and late convalescent-phase sera
among persons not recently vaccinated
Case classification
Confirmed: a clinically compatible illness that is laboratory confirmed
Comment
When other cases are known to be occurring, a less than fourfold rise in titer
between acute- and convalescent-phase serum may be considered significant.
Likewise, a less than fourfold fall between early and late convalescent-phase sera
may be important in these circumstances. Only confirmed cases should be re-
ported to the NNDSS. Illnesses due to strains of V. cholerae  other than toxigenic
V. cholerae  01 should not be reported as cases of cholera.
Dengue Fever
Clinical description
An acute febrile illness characterized by frontal headache, retro-ocular pain, muscle
and joint pain, and rash. The disease is transmitted by the Aedes aegypti  mosquito
and is confined to the tropics. Severe manifestations (dengue hemorrhagic fever
and dengue shock syndrome) are rare, but may be fatal.
Laboratory criteria for diagnosis
• Isolation of dengue virus from serum and/or autopsy tissue samples, or
• Demonstration of a fourfold or greater rise or fall in reciprocal IgG or IgM anti-
body titers in paired serum samples to one or more dengue virus antigens, or
• Demonstration of dengue virus antigen in autopsy tissue samples by im-
munofluorescence or by hybridization probe
Case classification
Probable: a clinically compatible illness with supportive serology (a reciprocal IgG
antibody titer of ≥1280 or a positive IgM antibody test on a single convalescent-
phase serum specimen to one or more dengue virus antigens)
Confirmed: a case that is laboratory confirmed
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Comment
Dengue hemorrhagic fever is defined as acute onset of fever with nonspecific
symptoms. This is followed by hemorrhagic manifestations that may include a
positive tourniquet test* and/or minor or major bleeding phenomena, thrombocy-
topenia (100,000/mm
3
), and hemoconcentration (hematocrit increased by ≥20%), or
other objective evidence of increasing capillary permeability; or decreasing hema-
tocrit after severe frank hemorrhage, such as upper gastrointestinal bleeding.
The definition for dengue shock syndrome follows all of the above criteria for den-




An upper respiratory tract illness characterized by sore throat, low-grade fever, and
an adherent membrane of the tonsil(s), pharynx, and/or nose without other appar-
ent cause (as reported by a health professional)
Laboratory criteria for diagnosis
• Isolation of Corynebacterium diphtheriae  from a clinical specimen
Case classification
Probable: meets the clinical case definition, is not laboratory confirmed, and is not
epidemiologically linked to a laboratory-confirmed case
Confirmed: meets the clinical case definition and is either laboratory confirmed or
epidemiologically linked to a laboratory-confirmed case
Comment
Cutaneous diphtheria should not be reported.
Encephalitis, Arboviral
Clinical description
Arboviral infection may result in a febrile illness of variable severity associated with
neurologic symptoms ranging from headache to aseptic meningitis or encephalitis.
Arboviral encephalitis cannot be distinguished clinically from infection with other
neurotropic viruses. Symptoms may include headache, confusion or other altera-
tions in sensorium, nausea, or vomiting. Signs may include evidence of elevated
intracranial pressure or meningeal irritation, cranial nerve palsies, paresis or
paralysis, altered reflexes, or convulsions. (See Aseptic Meningitis and Encephali-
tis, Primary.)
*Standard method (Wintrobe, 1967) utilizes a blood-pressure cuff to impede venous flow. A
test is considered positive if there are ≥20 petechiae/inch2.
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Laboratory criteria for diagnosis
• Fourfold or greater rise in serum antibody titer, or
• Isolation of virus from or demonstration of viral antigen in tissue, blood, cerebro-
spinal fluid (CSF), or other body fluid, or
• Specific IgM antibody in CSF
Case classification
Probable: a clinically compatible illness occurring during a period when arbovirus
transmission is likely to occur, and with the following supportive serology: a stable
(twofold or greater change) elevated antibody titer to an arbovirus, e.g., ≥320 by
hemagglutination inhibition, ≥128 by complement fixation, ≥256 by immunofluo-
rescence, ≥160 by neutralization, or a positive serologic result by enzyme immuno-
assay (EIA)
Confirmed: a clinically compatible illness that is laboratory confirmed
Comment
The time of year in which arboviral transmission is likely to occur depends on the
geographic location of exposure, the specific cycle of virus transmission, and local
climatic conditions.
Arboviruses causing encephalitis include the following:
• St. Louis encephalitis
• Western equine encephalitis
• Eastern equine encephalitis
• California encephalitis (includes infections from the following viruses: LaCrosse,
Jamestown Canyon, Snowshoe Hare, Trivittatus, and California viruses)
• Powassan encephalitis
• Other central nervous system infections transmitted by mosquitos, ticks, or
midges (Venezuelan equine encephalitis, Cache Valley encephalitis)
Encephalitis, Postinfectious (or Parainfectious)
Clinical description
Encephalitis or meningoencephalitis that follows or occurs in combination with
other viral illnesses that are not central nervous system illnesses, or after vaccine is
administered. Symptoms may be due to hypersensitivity reaction. Primary en-
cephalitis is excluded.
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Case classification
Confirmed: a clinically compatible illness diagnosed by a physician as postinfec-
tious (or parainfectious) encephalitis
Comment




An illness in which encephalitis is the major manifestation. Symptoms are due to
direct invasion and replication of the infectious agent in the central nervous sys-
tem, resulting in objective clinical evidence of cerebral or cerebellar dysfunction.
Postinfectious (or parainfectious) encephalitis is excluded.
Case classification
Confirmed: a clinically compatible illness diagnosed by a physician as primary en-
cephalitis
Comment
Laboratory studies are important in clinical diagnosis but are not required for re-
porting purposes.
Primary encephalitis is a category used for reporting to the NNDSS. This category
includes arboviral encephalitis and primary encephalitis of unspecified cause.
Foodborne Disease Outbreak
Clinical description
Symptoms of illness depend upon etiologic agent. (See Guidelines for Confirma-
tion of Foodborne and Waterborne Disease Outbreaks, in press.)
Laboratory criteria for diagnosis
Depends upon etiologic agent. (See Guidelines for Confirmation of Foodborne and
Waterborne Disease Outbreaks, in press.)
Definition
An incident in which two or more persons experience a similar illness after inges-
tion of a common food, and epidemiologic analysis implicates the food as the
source of the illness.
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Comment
There are two exceptions: one case of botulism or chemical poisoning constitutes
an outbreak.
Genital Herpes (Herpes Simplex Virus)
Clinical description
An illness characterized by visible, painful genital or anogenital lesions
Laboratory criteria for diagnosis
• Isolation of herpes simplex virus from cervix, urethra, or anogenital lesion, or
• Demonstration of virus by antigen detection technique in clinical specimens from
cervix, urethra, or anogenital lesion, or
• Demonstration of multinucleated giant cells on a Tzanck smear of scrapings from
an anogenital lesion
Case classification
Probable: a clinically compatible case (in which primary and secondary syphilis
have been ruled out by serology and darkfield microscopy, when available) with
either a diagnosis of genital herpes based on clinical presentation (without labora-
tory confirmation) or a history of one or more previous episodes of similar genital
lesions
Confirmed: a clinically compatible case that is laboratory confirmed
Comment
Herpes should be reported only once per patient. The first diagnosis for a patient
with no previous diagnosis should be reported.
Genital Warts
Clinical description
An infection characterized by the presence of visible, exophytic (raised) growths on
the internal or external genitalia, perineum, or perianal region
Laboratory criteria for diagnosis
• Histopathologic changes characteristic of human papillomavirus (HPV) infection
on biopsy or exfoliative cytology
Case classification
Probable: a clinically compatible case without histopathologic diagnosis and with-
out microscopic or serologic evidence that the growth is due to secondary syphilis
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Confirmed: a clinically compatible case that is laboratory confirmed
Giardiasis
Clinical description
An illness caused by the protozoan Giardia lamblia  and characterized by diarrhea,
abdominal cramps, bloating, weight loss, or malabsorption. Infected persons may
be asymptomatic.
Laboratory criteria for diagnosis
• Demonstration of G. lamblia  cysts in stool, or
• Demonstration of G. lamblia  trophozoites in stool, duodenal fluid, or small
bowel biopsy, or
• Demonstration of G. lamblia  antigen in stool by a specific immunodiagnostic
test such as enzyme-linked immunosorbent assay (ELISA)
Case classification
Confirmed, symptomatic: a laboratory-confirmed case associated with one or
more of the symptoms described above




A sexually transmitted infection commonly manifested by urethritis, cervicitis, or
salpingitis. Infection may be asymptomatic.
Laboratory criteria for diagnosis
• Isolation of Neisseria gonorrhoeae  from a clinical specimen, or
• Observation of gram-negative intracellular diplococci in a urethral smear ob-
tained from a man
Case classification
Probable: demonstration of gram-negative intracellular diplococci in an endocervi-
cal smear obtained from a woman, or a written (morbidity) report of gonorrhea
submitted by a physician
Confirmed: a case that is laboratory confirmed
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Granuloma Inguinale
Clinical description
A slowly progressive ulcerative disease of the skin and lymphatics of the genital
and perianal area caused by infection with Calymmatobacterium granulomatis. A
clinically compatible case would have one or more painless or minimally painful
granulomatous lesions in the anogenital area.
Laboratory criteria for diagnosis
• Demonstration of intracytoplasmic Donovan bodies in Wright or Giemsa-stained
smears or biopsies of granulation tissue
Case classification
Confirmed: a clinically compatible case that is laboratory confirmed
Haemophilus influenzae  (Invasive Disease)
Clinical description
Invasive disease due to Haemophilus influenzae  may produce any of several clini-
cal syndromes, including meningitis, bacteremia, epiglottitis, or pneumonia
Laboratory criteria for diagnosis
• Isolation of H. influenzae  from a normally sterile site
Case classification
Probable: a clinically compatible illness with detection of H. influenzae  type b anti-
gen in cerebrospinal fluid
Confirmed: a clinically compatible illness that is culture confirmed
Comment




A chronic bacterial disease characterized by the involvement of mainly skin, periph-
eral nerves, and the mucosa of the upper airway. Clinical forms of Hansen disease
represent a spectrum reflecting the cellular immune response to Mycobacterium
leprae. Typical of the major forms of the disease are the following characteristics:
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• Tuberculoid — one or a few well-demarcated, hypopigmented, and anesthetic
skin lesions, frequently with active, spreading edges and a clearing center; pe-
ripheral nerve swelling or thickening may also occur
• Lepromatous — a number of erythematous papules and nodules or an infiltration
of the face, hands, and feet with lesions in a bilateral and symmetrical distribu-
tion that progress to thickening of the skin
• Borderline (dimorphous) — skin lesions characteristic of both the tuberculoid
and lepromatous forms
• Indeterminate — early lesions, usually hypopigmented macules, without devel-
oped tuberculoid or lepromatous features
Laboratory criteria for diagnosis
• Demonstration of acid-fast bacilli in skin or dermal nerve, obtained from the full-
thickness skin biopsy of a lepromatous lesion
Case classification
Confirmed: a clinically compatible case that is laboratory confirmed.
Hepatitis, Viral
Clinical case definition
An illness with a) discrete onset of symptoms and b) jaundice or elevated serum
aminotransferase levels
Laboratory criteria for diagnosis
• Hepatitis A: IgM anti-HAV-positive
• Hepatitis B: IgM anti-HBc-positive (if done) or HBsAg-positive, and IgM anti-HAV-
negative (if done)
• Non-A, Non-B Hepatitis: 
1. IgM anti-HAV-negative, and
2. IgM anti-HBc-negative (if done) or HBsAg-negative, and
3. Serum aminotransferase levels >2 1/2 times the upper limit of normal
• Delta Hepatitis: HBsAg- or IgM anti-HBc-positive and anti-HDV-positive
Case classification
Confirmed: a case that meets the clinical case definition and is laboratory
confirmed
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Comment
A serologic test for IgG antibody to the recently described hepatitis C virus is avail-
able, and many cases of non-A, non-B hepatitis may be demonstrated to be due to
infection with the hepatitis C virus. With this assay, however, a prolonged interval
between onset of disease and detection of antibody may occur. Until a more spe-
cific test for acute hepatitis C becomes available, these cases should be reported




A febrile illness of ≥5 days’ duration, with at least four of the five following physical
findings and no other more reasonable explanation for the observed clinical
findings:
• Bilateral conjunctival injection
• Oral changes (erythema of lips or oropharynx, strawberry tongue, or fissuring of
the lips)
• Peripheral extremity changes (edema, erythema, or generalized or periungual
desquamation)
• Rash
• Cervical lymphadenopathy (at least one lymph node ≥1.5 cm in diameter)
Laboratory criteria for diagnosis
None
Case classification
Confirmed: a case that meets the clinical case definition
Comment
If fever disappears after intravenous gamma globulin therapy is started, fever may
be of <5 days’ duration, and the clinical case definition may still be met.
Legionellosis (Legionnaire’s Disease)
Clinical description
An illness with acute onset, commonly characterized by fever, cough, and pneumo-
nia that is confirmed by chest radiograph. Encephalopathy and diarrhea may also
be included.
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Laboratory criteria for diagnosis
• Isolation of Legionella  from lung tissue, respiratory secretions, pleural fluid,
blood, or other normally sterile sites, or
• Demonstration of a fourfold or greater rise in the reciprocal immunofluorescence
(IF) antibody titer to ≥128 against Legionella pneumophila  serogroup 1, or
• Demonstration of L. pneumophila  serogroup 1 in lung tissue, respiratory secre-
tions, or pleural fluid by direct fluorescence antibody testing, or
• Demonstration of L. pneumophila  serogroup 1 antigens in urine by radioimmu-
noassay
Case classification
Probable: a clinically compatible illness with demonstration of a reciprocal anti-
body titer ≥256 from a single convalescent-phase serum specimen
Confirmed: a case that is laboratory confirmed
Leptospirosis
Clinical description
An illness characterized by fever, headache, chills, myalgia, conjunctival suffusion,
and less frequently by meningitis, rash, jaundice, or renal insufficiency. Symptoms
may be biphasic.
Laboratory criteria for diagnosis
• Isolation of Leptospira  from a clinical specimen, or
• Fourfold or greater increase in Leptospira  agglutination titer between acute- and
convalescent-phase serum specimens obtained ≥2 weeks apart and studied at
the same laboratory, or
• Demonstration of Leptospira  in a clinical specimen by immunofluorescence
Case classification
Probable: A clinically compatible case with supportive serology (i.e. a Leptospira
agglutination titer of ≥200 in one or more serum specimens)
Confirmed: a clinically compatible case that is laboratory confirmed
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Listeriosis
Clinical description
Infection caused by Listeria monocytogenes, which may produce any of several
clinical syndromes, including stillbirths, listeriosis of the newborn, meningitis, bac-
teremia, or localized infections
Laboratory criteria for diagnosis
• Isolation of L. monocytogenes  from a normally sterile site
Case classification
Confirmed: a clinically compatible case that is laboratory confirmed
Lyme Disease
Clinical description
A systemic, tick-borne disease with protean manifestations, including derma-
tologic, rheumatologic, neurologic, and cardiac abnormalities. The best clinical
marker for the disease is the initial skin lesion, erythema migrans, that occurs
among 60%-80% of patients.
Clinical case definition
• Erythema migrans, or
• At least one late manifestation, as defined below, and laboratory confirmation of
infection
Laboratory criteria for diagnosis
• Isolation of Borrelia burgdorferi  from clinical specimen, or
• Demonstration of diagnostic levels of IgM and IgG antibodies to the spirochete in
serum or CSF, or
• Significant change in IgM or IgG antibody response to B. burgdorferi  in paired
acute- and convalescent-phase serum samples
Case classification
Confirmed: a case that meets one of the clinical case definitions above
Comment
This surveillance case definition was developed for national reporting of Lyme dis-
ease; it is NOT appropriate for clinical diagnosis.
Definition of terms used in the clinical description and case definition:
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A. Erythema migrans (EM)
For purposes of surveillance, EM is defined as a skin lesion that typically
begins as a red macule or papule and expands over a period of days to
weeks to form a large round lesion, often with partial central clearing. A soli-
tary lesion must reach at least 5 cm in size. Secondary lesions may also
occur. Annular erythematous lesions occurring within several hours of a tick
bite represent hypersensitivity reactions and do not qualify as EM. For most
patients, the expanding EM lesion is accompanied by other acute symptoms,
particularly fatigue, fever, headache, mild stiff neck, arthralgia, or myalgia.
These symptoms are typically intermittent. The diagnosis of EM must be
made by a physician. Laboratory confirmation is recommended for persons
with no known exposure.
 B. Late manifestations
Late manifestations include any of the following when an alternate explana-
tion is not found:
•  Musculoskeletal system
Recurrent, brief attacks (weeks or months) of objective joint swelling in
one or a few joints, sometimes  followed by chronic arthritis in one or a
few joints. Manifestations not considered as criteria for diagnosis include
chronic progressive arthritis not preceded by brief attacks and chronic
symmetrical polyarthritis. Additionally, arthralgia, myalgia, or fibromyal-
gia syndromes alone are not criteria for musculoskeletal involvement.
• Nervous system
Any of the following, alone or in combination:
Lymphocytic meningitis; cranial neuritis, particularly facial palsy (may be
bilateral); radiculoneuropathy; or, rarely, encephalomyelitis. Encephalo-
myelitis must be confirmed by showing antibody production against
B. burgdorferi  in the cerebrospinal fluid (CSF), demonstrated by a higher
titer of antibody in CSF than in serum. Headache, fatigue, paresthesia, or
mild stiff neck alone are not criteria for neurologic involvement.
• Cardiovascular system
Acute onset, high-grade (2° or 3°) atrioventricular conduction defects that
resolve in days to weeks and are sometimes associated with myocarditis.
Palpitations, bradycardia, bundle branch block, or myocarditis alone are
not criteria for cardiovascular involvement.
C. Exposure
Exposure is defined as having been in wooded, brushy, or grassy areas (po-
tential tick habitats) in a county in which Lyme disease is endemic no more
than 30 days before onset of EM. A history of tick bite is NOT required.
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D. Disease endemic to county
A county in which Lyme disease is endemic is one in which at least two defi-
nite cases have been previously acquired or in which a known tick vector has
been shown to be infected with B. burgdorferi
E. Laboratory confirmation
As noted above, laboratory confirmation of infection with B. burgdorferi  is
established when a laboratory isolates the spirochete from tissue or body
fluid, detects diagnostic levels of IgM or IgG antibodies to the spirochete in
serum or CSF, or detects a significant change in antibody levels in paired
acute- and convalescent-phase serum samples. States may determine the
criteria for laboratory confirmation and diagnostic levels of antibody. Syphi-
lis and other known causes of biologic false-positive serologic test results




Infection with L1, L2, or, L3 serovars of Chlamydia trachomatis  may result in a
disease characterized by genital lesions, suppurative regional lymphadenopathy,
or hemorrhagic proctitis. The infection is usually sexually transmitted.
Laboratory criteria for diagnosis
• Isolation of C. trachomatis, serotype L1, L2, or L3, from clinical specimen, or
• Demonstration of inclusion bodies by immunofluorescence in leukocytes of an
inguinal lymph node (bubo) aspirate, or
• Positive microimmunofluorescent serologic test for a lymphogranuloma ven-
ereum strain of C. trachomatis  (in a clinically compatible case)
Case classification
Probable: a clinically compatible case with one or more tender fluctuant inguinal
lymph nodes or characteristic proctogenital lesions with supportive laboratory
findings of a single C. trachomatis  complement fixation (CF) titer of >64
Confirmed: a case that is laboratory confirmed
Malaria
Clinical description
Signs and symptoms are variable, but chills followed by fever and sweating consti-
tute the classic malaria paroxysm. The diagnosis should be considered for any
person who has been exposed to infection. Complications such as cerebral malaria
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may occur in Plasmodium falciparum  infection. Asymptomatic parasitemia may
occur among immune persons.
Laboratory criteria for diagnosis
• Demonstration of malaria parasites in blood films
Case classification
Confirmed: a person’s first attack of laboratory-confirmed malaria that occurs in the
United States, regardless of whether the person has experienced previous attacks
of malaria while outside the country
Comment
A subsequent attack experienced by the same person but caused by a differ-
ent Plasmodium  species is counted as an additional case. A repeated attack
experienced by the same person and caused by the same species in the United
States is not considered an additional case.
Blood smears from doubtful cases should be referred to the National Malaria Re-
pository, CDC, for confirmation of the diagnosis.
In addition, cases are classified according to the following World Health Organiza-
tion categories:
Autochthonous:
Indigenous—malaria acquired by mosquito transmission in an area where ma-
laria is a regular occurrence
Introduced—malaria acquired by mosquito transmission from an imported case
in an area where malaria is not a regular occurrence
Imported: malaria acquired outside a specific area (the United States and its territo-
ries)
Induced: malaria acquired through artificial means (e.g., blood transfusion, com-
mon syringes, or malariotherapy)
Relapsing: renewed manifestation (of clinical symptoms and/or parasitemia) of
malarial infection that is separated from previous manifestations of the same infec-
tion by an interval greater than any interval due to the normal periodicity of the
paroxysms
Cryptic: an isolated case of malaria not associated with secondary cases, as deter-
mined by appropriate epidemiologic investigations
Measles
Clinical case definition
An illness characterized by all of the following clinical features:
• a generalized rash lasting ≥3 days
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• a temperature ≥38.3 C (101 F)
• cough, or coryza, or conjunctivitis
Laboratory criteria for diagnosis
• Isolation of measles virus from a clinical specimen, or
• Significant rise in measles antibody level by any standard serologic assay, or
• Positive serologic test for measles IgM antibody
Case classification
Suspect: any rash illness with fever
Probable: meets the clinical case definition, has no or noncontributory serologic or
virologic testing, and is not epidemiologically linked to a probable or confirmed
case
Confirmed: a case that is laboratory confirmed or that meets the clinical case
definition and is epidemiologically linked to a confirmed or probable case. A labo-
ratory-confirmed case does not need to meet the clinical case definition.
Comment
Two probable cases that are epidemiologically linked would be considered con-
firmed, even in the absence of laboratory confirmation. Only confirmed cases
should be reported to the NNDSS.
Meningococcal Disease
Clinical description
Meningococcal disease presents most commonly as meningitis and/or meningo-
coccemia that may progress rapidly to purpura fulminans, shock, and death.
However, other manifestations may be observed.
Laboratory criteria for diagnosis
• Isolation of Neisseria meningitidis  from a normally sterile site
Case classification
Probable: a positive antigen test in cerebrospinal fluid or clinical purpura fulminans
in the absence of a positive blood culture
Confirmed: a clinically compatible case that is culture confirmed
Comment
Antigen test results in urine or serum are unreliable for diagnosing meningococcal
disease.
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Mucopurulent Cervicitis
Clinical description
Cervical inflammation that is not the result of infection with Neisseria gonorrhoeae
or Trichomonas vaginalis. Cervical inflammation is defined by the presence of one
of the following criteria:
• Mucopurulent secretion (from the endocervix) that is yellow or green when
viewed on a white, cotton-tipped swab (positive swab test)
• Induced endocervical bleeding (bleeding when the first swab is placed in the en-
docervix)
Laboratory criteria for diagnosis
• No evidence of N. gonorrhoeae  infection by culture or Gram stain and no evi-
dence of T. vaginalis  on wet mount
Case classification
Confirmed: a clinically compatible case among females for whom gonorrhea and
trichomonas infection are not found
Comment
Mucopurulent cervicitis (MPC) is a clinical diagnosis of exclusion. The syndrome
may result from infection with several agents (see Chlamydia trachomatis
Infection). If gonorrhea, trichomoniasis, and chlamydia are excluded, a clinically
compatible case should be classified as MPC. An illness among women that meets




An illness with acute onset of unilateral or bilateral tender, self-limited swelling of
the parotid or other salivary gland, lasting ≥2 days, and without other apparent
cause (as reported by a health professional)
Laboratory criteria for diagnosis
• Isolation of mumps virus from clinical specimen, or
• Significant rise in mumps antibody level by any standard serologic assay, or
• Positive serologic test for mumps IgM antibody
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Case classification
Probable: meets the clinical case definition, has no or noncontributory serologic or
virologic testing, and is not epidemiologically linked to a confirmed or probable
case
Confirmed: a case that is laboratory confirmed or that meets the clinical case
definition and is epidemiologically linked to a confirmed or probable case. A
laboratory-confirmed case does not need to meet the clinical case definition.
Comment
Two probable cases that are epidemiologically linked would be considered con-
firmed, even in the absence of laboratory confirmation.
Nongonococcal Urethritis
Clinical description
Urethral inflammation that is not the result of infection with Neisseria gonorrhoeae.
Urethral inflammation may be diagnosed by the presence of one of the following
criteria:
• A visible abnormal urethral discharge (excludes scant amounts of clear mucus)
• A positive leukocyte esterase test from men <60  years of age without a history of
kidney disease or bladder infection, prostate enlargement, urogenital anatomic
anomaly, or recent urinary tract instrumentation
• Microscopic evidence of urethritis (≥5 WBC per high-power field) on a Gram stain
of a urethral smear
Laboratory criteria for diagnosis
• No evidence of N. gonorrhoeae  infection by culture or Gram stain
Case classification
Confirmed: a clinically compatible case among males in whom gonorrhea is not
found, either by culture or Gram stain
Comment
Nongonococcal urethritis (NGU) is a clinical diagnosis of exclusion. The syndrome
may result from infection with several agents (see Chlamydia trachomatis  Infec-
tion). A clinically compatible case excluding gonorrhea and chlamydia should be
classified as NGU. An illness among men that meets the case definition of NGU and
C. trachomatis  infection should be classified as chlamydia.
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Pelvic Inflammatory Disease
 (NOTE: The following definition is being reviewed by CSTE and CDC, and changes
are anticipated.)
Clinical case definition
A clinical syndrome resulting from the ascending spread of microorganisms from
the vagina and endocervix to the endometrium, fallopian tubes, and/or contiguous
structures. All of the following clinical criteria must be present:
• Abdominal direct tenderness
• Tenderness with motion of the cervix
• Adnexal tenderness
In addition to all of the above criteria, at least one of the following findings must
also be present:
• Meets the surveillance case definition of Chlamydia trachomatis  infection or
gonorrhea
• Temperature >38 C
• Leukocytosis >10,000 WBC/mm3
• Purulent material in the peritoneal cavity obtained by culdocentesis or laparo-
scopy
• Pelvic abscess or inflammatory complex on bimanual examination or by sonog-
raphy
• Patient is a sexual contact of a person known to have gonorrhea, chlamydia, or
nongonococcal urethritis
Case classification
Confirmed: a case that meets the clinical case definition
Comment
For reporting purposes, a clinician’s report of pelvic inflammatory disease should
be counted as a case.
Pertussis
Clinical case definition
A cough illness lasting at least 2 weeks with one of the following: paroxysms of
coughing, inspiratory “whoop,” or post-tussive vomiting — and without other ap-
parent cause (as reported by a health professional)
Vol. 39 / No. RR-13 MMWR 27
Laboratory criteria for diagnosis
• Isolation of Bordetella pertussis  from clinical specimen
Case classification
Probable: meets the clinical case definition, is not laboratory confirmed, and is not
epidemiologically linked to a laboratory-confirmed case
Confirmed: a clinically compatible case that is laboratory confirmed or epidem-
iologically linked to a laboratory-confirmed case
Comment
The clinical case definition above is appropriate for endemic or sporadic cases. In
outbreak settings, a case may be defined as a cough illness lasting at least 2 weeks
(as reported by a health professional). Because direct fluorescent antibody testing
of nasopharyngeal secretions has been shown in some studies to have low sensi-
tivity and variable specificity (5,6 ), it should not be relied on as a criterion for
laboratory confirmation.
Both probable and confirmed cases should be reported to the NNDSS.
Plague
Clinical description
A disease characterized by fever and leukocytosis that presents in one or more of
the following principal clinical forms:
• Regional lymphadenitis (bubonic plague)
• Septicemia without an evident bubo (septicemic plague)
• Plague pneumonia, resulting from hematogenous spread in bubonic or sep-
ticemic cases (secondary plague pneumonia ) or inhalation of infectious droplets
(primary plague pneumonia)
• Pharyngitis and cervical lymphadenitis resulting from exposure to larger infec-
tious droplets or ingestion of infected tissues (pharyngeal plague)
Plague is transmitted to humans by fleas or by direct exposure to infected tissues
or respiratory droplets.
Laboratory criteria for diagnosis
• Isolation of Yersinia pestis  from a clinical specimen, or
• Fourfold or greater change in serum antibody to Y. pestis
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Case classification
Probable: a clinically compatible illness with supportive laboratory results (demon-
stration of a single serologic test result suggestive of recent infection with no
history of immunization, or demonstration of a Fraction I antigen in blood, bubo
aspirate, or tissue by antigen detection—enzyme-linked immunosorbent assay
(ELISA) or fluorescent assay (FA)
Confirmed: a case that is laboratory confirmed
Poliomyelitis, Paralytic
Clinical case definition
Acute onset of a flaccid paralysis of one or more limbs with decreased or absent
tendon reflexes in the affected limbs, without other apparent cause, and without
sensory or cognitive loss (as reported by a physician)
Case classification
Probable: a case that meets the clinical case definition
Confirmed: a case that meets the clinical case definition and in which the patient
has a neurologic deficit 60 days after onset of initial symptoms, has died, or has
unknown follow-up status
Comment
All suspected cases of paralytic poliomyelitis are reviewed by a panel of expert
consultants before final classification occurs. Only confirmed cases are included in




An illness characterized by fever, chills, headache, photophobia, lower or upper
respiratory disease, and myalgia
Laboratory criteria for diagnosis
• Isolation of Chlamydia psittaci  from a clinical specimen, or
• Fourfold or greater increase in psittacosis complement-fixing (CF) antibody titer
(≥32) between two serum specimens obtained ≥2 weeks apart and studied at the
same laboratory
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Case classification
Probable: a clinically compatible illness that is epidemiologically linked to a con-
firmed case, or with supportive serology (i.e., a psittacosis CF titer of ≥32 in one or
more serum specimens obtained after onset of symptoms)
Confirmed: a clinically compatible illness that is laboratory confirmed
Comment
The serologic findings noted above may also occur as a result of infection with
Chlamydia trachomatis  or Chlamydia pneumoniae.
Rabies, Animal
Laboratory criteria for diagnosis
• A positive direct fluorescent antibody test (preferably performed on central nerv-
ous system tissue)
• Isolation of rabies virus (in cell culture or in a laboratory animal)
Case classification
Confirmed: a case that is laboratory confirmed
Rabies, Human
Clinical description
Rabies is an acute encephalomyelitis that almost always progresses to coma or
death within 10 days of the first symptom.
Laboratory criteria for diagnosis
• Detection by direct fluorescent antibody of viral antigens in a clinical specimen
(preferably the brain or the nerves surrounding hair follicles in the nape of the
neck), or
• Isolation (in cell culture or in a laboratory animal) of rabies virus from saliva,
cerebrospinal fluid (CSF), or central nervous system tissue, or
• Identification of a rabies-neutralizing antibody titer ≥5 (complete neutralization)
in the serum or CSF of an unvaccinated person
Case classification
Confirmed: a clinically compatible illness that is laboratory confirmed
Comment
Laboratory confirmation by all of the above methods is strongly recommended.
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Reye Syndrome
Clinical case definition
An illness that meets all of the following criteria:
• Acute, noninflammatory encephalopathy that is documented clinically by a) an
alteration in consciousness and, if available, b) a record of the CSF containing
≤8 leukocytes/mm3 or a histologic specimen demonstrating cerebral edema with-
out perivascular or meningeal inflammation
• Hepatopathy documented by either a) a liver biopsy or an autopsy considered to
be diagnostic of Reye syndrome or b) a threefold or greater increase in the levels
of the serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-pyru-
vic transaminase (SGPT), or serum ammonia
• No more reasonable explanation for the cerebral and hepatic abnormalities
Case classification
Confirmed: a case that meets the clinical case definition
Rheumatic Fever
Clinical description
An inflammatory illness that occurs as a delayed sequel to group A streptococcal
infection
Major criteria: carditis, polyarthritis, chorea, subcutaneous nodules, and erythema
marginatum
Minor criteria: a) previous rheumatic fever or rheumatic heart disease, b) arthralgia,
c) fever, d) elevated erythrocyte sedimentation rate, positive C-reactive protein, or
leukocytosis, and e) prolonged PR interval
Laboratory criteria for diagnosis
• No specific laboratory test exists for the diagnosis of rheumatic fever.
Case classification
Confirmed: an illness characterized by a) two major criteria or one major and two
minor criteria (as described above) and b) supporting evidence of preceding group
A streptococcal infection (7 )
Comment
Supporting evidence to confirm streptococcal infection includes increased anti-
streptolysin-O or other streptococcal antibodies, throat culture positive for group A
streptococcus, or recent scarlet fever. The absence of supporting evidence of pre-
ceding streptococcal infection should make the diagnosis doubtful, except in
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Sydenham chorea or low-grade carditis when rheumatic fever is first discovered
after a long latent period from the antecedent infection.
Rocky Mountain Spotted Fever
Clinical description
An illness most commonly characterized by acute onset and fever, usually accom-
panied by myalgia, headache, and petechial rash (on the palms and soles in
two-thirds of the cases)
Laboratory criteria for diagnosis
• Fourfold or greater rise in antibody titer to the spotted fever group antigen by
immunofluorescent antibody (IFA), complement fixation (CF), latex agglutination
(LA), microagglutination (MA), or indirect hemagglutination (IHA) test, or a single
titer ≥64 by IFA or ≥16 by CF
• Demonstration of positive immunofluorescence of skin lesion (biopsy) or organ
tissue (autopsy)
• Isolation of Rickettsia rickettsii  from clinical specimen
Case classification
Probable: a clinically compatible case with supportive serology (fourfold rise in titer
or a single titer ≥320 by Proteus  OX-19 or OX-2, or a single titer ≥128 by LA, IHA, or
MA test)
Confirmed: a case that is laboratory confirmed
Rubella
Clinical case definition
An illness with all of the following characteristics:
• Acute onset of generalized maculopapular rash
• Temperature >37.2 C (>99 F), if measured
• Arthralgia/arthritis, or lymphadenopathy, or conjunctivitis
Cases meeting the measles case definition are excluded. Also excluded are cases
with serology compatible with recent measles virus infection.
Laboratory critera for diagnosis
• Isolation of rubella virus, or
• Significant rise in rubella antibody level by any standard serologic assay, or
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• Positive serologic test for rubella IgM antibody
Case classification
Suspect: any generalized rash illness of acute onset
Probable: a case that meets the clinical case definition, has no or noncontributory
serologic or virologic testing, and is not epidemiologically linked to a laboratory-
confirmed case
Confirmed: a case that is laboratory confirmed or that meets the clinical case defi-
nition and is epidemiologically linked to a laboratory-confirmed case
Rubella Syndrome, Congenital
Clinical description
An illness of newborns resulting from rubella infection in utero  and characterized
by symptoms from the following categories:
(A) Cataracts/congenital glaucoma, congenital heart disease, loss of hearing,
pigmentary retinopathy
Associated symptoms may be:
(B) Purpura, splenomegaly, jaundice, microcephaly, mental retardation, men-
ingoencephalitis, radiolucent bone disease
Clinical case definition
Presence of any defects or laboratory data consistent with congenital rubella infec-
tion (as reported by a health professional)
Laboratory criteria for diagnosis
• Isolation of rubella virus, or
• Demonstration of rubella-specific IgM antibody, or
• An infant’s rubella antibody level that persists above and beyond that expected
from passive transfer of maternal antibody (i.e., rubella HI titer that does not drop
at the expected rate of a twofold dilution per month)
Case classification
Possible: a case with some compatible clinical findings but not meeting the criteria
for a compatible case
Compatible: a case that is not laboratory confirmed and that has any two complica-
tions listed in (A) above, or one complication from (A) and one from (B)
Confirmed: a clinically compatible case that is laboratory confirmed
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Comment
In compatible cases, either or both of the eye-related findings (cataracts and con-
genital glaucoma) count as a single complication.
Salmonellosis
Clinical description
An illness of variable severity commonly manifested by diarrhea, abdominal pain,
nausea, and sometimes vomiting. Asymptomatic infections may occur, and the or-
ganism may cause extraintestinal infections.
Laboratory criteria for diagnosis
• Isolation of Salmonella  from a clinical specimen
Case classification
Probable: a clinically compatible illness that is epidemiologically linked to a con-
firmed case
Confirmed: a case that is laboratory confirmed
Comment
Both probable and confirmed cases are reported to the NNDSS, but only confirmed
cases are reported to the laboratory-based surveillance system operated by the
Enteric Diseases Branch, Center for Infectious Diseases, CDC. Both asymptomatic
infections and infections at sites other than the gastrointestinal tract, if laboratory
confirmed, are considered confirmed cases.
Shigellosis
Clinical description
An illness of variable severity characterized by diarrhea, fever, nausea, cramps, and
tenesmus. Asymptomatic infections occur.
Laboratory criteria for diagnosis
• Isolation of Shigella  from a clinical specimen
Case classification
Probable: a clinically compatible illness that is epidemiologically linked to a con-
firmed case
Confirmed: a case that is laboratory confirmed
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Comment
Both probable and confirmed cases are reported to the NNDSS, but only confirmed
cases are reported to the laboratory-based surveillance system operated by the
Enteric Diseases Branch, Center for Infectious Diseases, CDC. Confirmation is
based on laboratory findings, and clinical illness is not required.
Spinal Cord Injury
Clinical case definition
An acute traumatic lesion of the neural elements in the spinal canal, resulting in
temporary or permanent sensory deficit, motor deficit, or bowel/bladder dysfunc-
tion
Case classification
Confirmed: a case that meets the clinical case definition
Syphilis
Syphilis is a complex, sexually transmitted disease with a highly variable clinical
course. Classification by a clinician with expertise in syphilis may take precedence
over the following case definitions developed for surveillance purposes.
Primary Syphilis
Clinical description
The characteristic lesion of primary syphilis is the chancre, but atypical primary
lesions may occur.
Laboratory criteria for diagnosis
• Demonstration of Treponema pallidum  in clinical specimens by darkfield, fluo-
rescent antibody, or equivalent microscopic methods
Case classification
Probable: a clinically compatible case with one or more ulcers (chancres) consis-
tent with primary syphilis and a reactive serologic test
Confirmed: a clinically compatible case that is laboratory confirmed
Secondary Syphilis
Clinical description
A stage of infection due to Treponema pallidum, characterized by localized or dif-
fuse mucocutaneous lesions and generalized lymphadenopathy. Constitutional
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symptoms are common, and clinical manifestations are protean. The primary chan-
cre may still be present.
Laboratory criteria for diagnosis
• Demonstration of T. pallidum  in clinical specimens by darkfield, fluorescent anti-
body, or equivalent microscopic methods
Case classification
Probable: a clinically compatible case with a reactive nontreponemal (VDRL, RPR)
test titer of ≥4
Confirmed: a clinically compatible case that is laboratory confirmed
Latent Syphilis
Clinical description
A stage of infection due to Treponema pallidum  in which organisms persist in the
body of the infected person without causing symptoms or signs. Latent syphilis is
subdivided into early, late, and unknown syphilis categories based upon the length
of elapsed time from initial infection.
Case classification
Presumptive: no clinical signs or symptoms of syphilis and the presence of one of
the following:
• No past diagnosis of syphilis and a reactive nontreponemal test, and a reactive
treponemal (fluorescent treponemal antibody-absorbed [FTA-ABS], microhe-
magglutination assay for antibody to Treponema pallidum  [MHA-TP]) test
• A past history of syphilis therapy and a current nontreponemal test titer demon-
strating fourfold or greater increase from the last nontreponemal test titer
Early Latent Syphilis
Clinical description
A subcategory of latent syphilis. When initial infection has occurred within the pre-
vious 12 months, latent syphilis is classified as early.
Case classification
Presumptive: latent syphilis (see above) of a person who has evidence of having
acquired the infection within the previous 12 months based on one or more of the
following criteria:
• A nonreactive serologic test for syphilis or a nontreponemal titer that has
dropped fourfold within the past 12 months
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• A history of symptoms consistent with primary or secondary syphilis without a
history of subsequent treatment in the past 12 months
• A history of sexual exposure to a partner with confirmed or presumptive primary
or secondary syphilis, or presumptive early latent syphilis, and no history of
treatment in the past 12 months
• Reactive nontreponemal and treponemal tests from an individual whose only
possible exposure occurred within the preceding 12 months
Late Latent Syphilis
Clinical description
A subcategory of latent syphilis. When initial infection has occurred >1 year pre-
viously, latent syphilis is classified as late.
Case classification
Presumptive: latent syphilis (see above) of a patient who shows no evidence of
having acquired the disease within the past 12 months (see Early Latent Syphilis)




A subcategory of latent syphilis. When the date of initial infection cannot be estab-
lished as occurring within the previous year, and the patient’s age and titer meet
criteria described below, latent syphilis is classified as unknown latent.
Case classification
Presumptive: latent syphilis (see above) that does not meet the criteria for early
latent syphilis, and the patient is 13–35 years of age with a nontreponemal test
serologic titer of ≥32
Neurosyphilis
Clinical description
Evidence of CNS infection with Treponema pallidum
Laboratory criteria for diagnosis
• A reactive serologic test for syphilis and reactive VDRL in cerebrospinal fluid
(CSF)
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Case classification
Presumptive: syphilis of any stage, a negative VDRL in CSF, and both of the
following:
• Elevated CSF protein or leukocyte count in the absence of other known causes of
these abnormalities
• Clinical symptoms or signs consistent with neurosyphilis without other known
causes for these clinical abnormalities




A condition caused by infection in utero  with Treponema pallidum. A wide spec-
trum of severity exists, and only severe cases are clinically apparent at birth. An
infant (<2 years) may have signs such as hepatosplenomegaly, characteristic skin
rash, condyloma lata, snuffles, jaundice (non-viral hepatitis), pseudoparalysis, ane-
mia, or edema (nephrotic syndrome and/or malnutrition). An older child may have
stigmata such as interstitial keratitis, nerve deafness, anterior bowing of shins,
frontal bossing, mulberry molars, Hutchinson teeth, saddle nose, rhagades, or Clut-
ton joints.
Laboratory criteria for diagnosis
• Demonstration of T. pallidum  by darkfield microscopy, fluorescent antibody, or
other specific stains in specimens from lesions, placenta, umbilical cord, or
autopsy material
Case classification
Presumptive: the infection of an infant whose mother had untreated or inade-
quately treated* syphilis at delivery, regardless of signs in the infant; or the
infection of an infant or child who has a reactive treponemal test for syphilis and
any one of the following:
• Any evidence of congenital syphilis on physical examination
• Any evidence of congenital syphilis on long bone x-ray
• A reactive cerebrospinal fluid (CSF) VDRL
• An elevated CSF cell count or protein (without other cause)
• A reactive test for fluorescent treponemal antibody absorbed-19S-IgM antibody
*Inadequate treatment consists of any non-penicillin therapy or penicillin given <30 days before
delivery.
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Confirmed: a case (among infants) that is laboratory confirmed
Comment
Congenital and acquired syphilis may be difficult to distinguish when a child is se-
ropositive after infancy. Signs of congenital syphilis may not be obvious, and
stigmata may not yet have developed.
Abnormal values for CSF VDRL, cell count, and protein, as well as IgM antibodies,
may be found in either congenital or acquired syphilis. Findings on long bone
x-rays may help, since x-ray changes in the metaphysis and epiphysis are consid-
ered classic for congenitally acquired disease. The decision may ultimately be
based on maternal history and clinical judgment. The possibility of sexual abuse
should be considered.
For reporting purposes, congenital syphilis includes cases of congenitally acquired
syphilis among infants and children, as well as syphilitic stillbirths.
Syphilitic Stillbirth
Clinical case definition
A fetal death that occurs after a 20-week gestation or in which the fetus weighs
>500 g, and the mother had untreated or inadequately treated* syphilis at delivery
Comment




Acute onset of hypertonia and/or painful muscular contractions (usually of the
muscles of the jaw and neck) and generalized muscle spasms without other appar-
ent medical cause (as reported by a health professional)
Case classification
Confirmed: a case that meets the clinical case definition
Toxic Shock Syndrome
Clinical case definition
An illness with the following clinical manifestations:
• Fever — temperature ≥38.9 C (102 F)
• Rash—diffuse macular erythroderma
*Inadequate treatment consists of any non-penicillin therapy or penicillin given <30 days before
delivery.
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• Desquamation—1–2 weeks after onset of illness, particularly palms and soles
• Hypotension—systolic blood pressure ≤90 mm Hg for adults or less than fifth
percentile by age for children <16 years of age; orthostatic drop in diastolic blood
pressure ≥15 mm Hg from lying to sitting, orthostatic syncope, or orthostatic diz-
ziness
• Multisystem involvement — three or more of the following:
– Gastrointestinal: vomiting or diarrhea at onset of illness 
– Muscular: severe myalgia or creatine phosphokinase level at least twice
the upper limit of normal for laboratory
– Mucous membrane: vaginal, oropharyngeal, or conjunctival hyperemia
– Renal: blood urea nitrogen or creatinine at least twice the upper limit of
normal for laboratory or urinary sediment with pyuria (≥5 leukocytes per
high-power field) in the absence of urinary tract infection
– Hepatic: total bilirubin, serum glutamic-oxaloacetic transaminase (SGOT),
or serum glutamic-pyruvic transaminase (SGPT) at least twice the upper
limit of normal for laboratory
– Hematologic: platelets <100,000/mm3
– Central nervous system: disorientation or alterations in consciousness
without focal neurologic signs when fever and hypotension are absent
•  Negative results on the following tests, if obtained:
– Blood, throat, or cerebrospinal fluid cultures (blood culture may be posi-
tive for Staphylococcus aureus )
– Rise in titer to Rocky Mountain spotted fever, leptospirosis, or measles
Case classification
Probable: a case with five of the six clinical findings described above
Confirmed: a case with all six of the clinical findings described above, including
desquamation, unless the patient dies before desquamation could occur
Trichinosis
Clinical description
A disease caused by ingestion of larvae of Trichinella spiralis  that has variable clini-
cal manifestations. Common signs and symptoms among symptomatic persons
include eosinophilia, fever, myalgia, and periorbital edema.
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Laboratory criteria for diagnosis
• Demonstration of larvae of cysts of T. spiralis  on muscle biopsy, or
• Positive serology for T. spiralis
Case classification
Confirmed: a clinically compatible illness that is laboratory confirmed
Comment
In an outbreak setting, at least one case must be laboratory confirmed. Associated
cases should be reported as confirmed if the patient shared an epidemiologically
implicated meal or ate an epidemiologically implicated meat product and has either
a positive serology for trichinosis or a clinically compatible illness.
Tuberculosis
Clinical description
A chronic bacterial infection due to Mycobacterium tuberculosis, characterized
pathologically by the formation of granulomas. The most common site of infection
is the lung, but other organs may be involved.
Clinical case definition
A case that meets the following criteria:
• A positive tuberculin skin test
• Other signs and symptoms compatible with tuberculosis, such as an abnormal,
unstable (worsening or improving) chest x-ray, or clinical evidence of current
disease
• Treatment with two or more antituberculosis medications
• Completed diagnostic evaluation
Laboratory criteria for diagnosis
• Isolation of M. tuberculosis  from a clinical specimen, or
• Demonstration of M. tuberculosis  from a clinical specimen by DNA probe or my-
colic acid pattern on high-pressure liquid chromatography, or
• Demonstration of acid-fast bacilli in clinical specimen when a culture has not
been or cannot be obtained
Case classification
Confirmed: a case that is laboratory confirmed or, in the absence of laboratory con-
firmation, a case that meets the clinical case definition
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Comment
A case should not be counted twice within any consecutive 12-month period. How-
ever, cases in which the patients had verified disease in the past should be reported
again if the patients were discharged. Cases also should be reported again if they
were lost to supervision for >12 months and disease can be verified again.
Mycobacterial diseases other than those caused by M. tuberculosis  should not be
counted in tuberculosis morbidity statistics unless there is concurrent tuberculosis.
Tularemia
Clinical description
An illness characterized by several distinct forms, including:
• Ulceroglandular — cutaneous ulcer with regional lymphadenopathy
• Glandular — regional lymphadenopathy with no ulcer
• Oculoglandular — conjunctivitis with preauricular lymphadenopathy
• Intestinal — pharyngitis, intestinal pain, vomiting, and diarrhea
• Pneumonic — primary pleuropulmonary disease
• Typhoidal — febrile illness without early localizing signs and symptoms
Clinical diagnosis is supported by evidence or history of a tick or deerfly bite, expo-
sure to tissues of a mammalian host of Francisella tularensis, or exposure to
potentially contaminated water.
Laboratory criteria for diagnosis
• Isolation of F. tularensis  from a clinical specimen, or
• Demonstration of F. tularensis  in a clinical specimen by immunofluorescence, or
• Fourfold or greater rise in agglutination titer between acute- and convalescent-
phase serum specimens obtained ≥2 weeks apart, analyzed at the same time, and
in the same laboratory
Case classification
Probable: a clinically compatible case with supportive serologic results (tularemia
agglutination titer of ≥160 in one or more serum specimens obtained after onset of
symptoms)
Confirmed: a case that is laboratory confirmed
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Typhoid Fever
Clinical description
An illness caused by Salmonella typhi  that is often characterized by insidious onset
of sustained fever, headache, malaise, anorexia, relative bradycardia, constipation
or diarrhea, and nonproductive cough. However, many mild and atypical infections
occur. Carriage of S. typhi  may be prolonged.
Laboratory criteria for diagnosis
• Isolation of S. typhi  from blood, stool, or other clinical specimen
Case classification
Probable: a clinically compatible illness that is epidemiologically linked to a con-
firmed case in an outbreak
Confirmed: a clinically compatible illness that is laboratory confirmed
Comment
Isolation of the organism is required for confirmation. Serologic evidence alone is
not sufficient for diagnosis. Asymptomatic carriage should NOT be reported as ty-
phoid fever. Isolates of S. typhi  are reported to the Enteric Diseases Branch, Center




An illness with acute onset of diffuse (generalized) papulovesicular rash without
other apparent cause (as reported by a health professional)
Laboratory criteria for diagnosis
• Isolation of varicella virus from a clinical specimen, or
• Significant rise in varicella antibody level by any standard serologic assay
Case classification
Probable: a case that meets the clinical case definition, is not laboratory confirmed,
and is not epidemiologically linked to another probable or confirmed case
Confirmed: a case that is laboratory confirmed or that meets the clinical case defi-
nition and is epidemiologically linked to a confirmed or probable case
Comment
Two probable cases that are epidemiologically linked would be considered con-
firmed, even in the absence of laboratory confirmation.
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Waterborne Disease Outbreak
Clinical description
Symptoms of illness depend upon etiologic agent. (See Guidelines for Confirma-
tion of Foodborne and Waterborne Disease Outbreaks, in press.)
Laboratory criteria for diagnosis
Depends upon etiologic agent. (See Guidelines for Confirmation of Foodborne and
Waterborne Disease Outbreaks, in press.)
Definition
An incident in which two or more persons experience a similar illness after
consumption or use of water intended for drinking, and epidemiologic evidence
implicates the water as the source of the illness.
Comment
In addition, a single case of chemical poisoning constitutes an outbreak if labora-
tory studies indicate that the water has been contaminated by the chemical. Other
outbreaks that should be reported include a) epidemiologic investigations of out-
breaks of gastroenteritis (even if not waterborne) on ocean-going passenger
vessels that call on U.S. ports, and b) outbreaks of illness associated with exposure
to recreational water. Disease outbreaks associated with water used for recrea-
tional purposes should meet the same criteria used for waterborne outbreaks
associated with drinking water. However, outbreaks associated with recreational
water involve exposure to or unintentional ingestion of fresh or marine water, ex-
cluding wound infections caused by water-related organisms.
Yellow Fever
Clinical description
A mosquito-borne, viral illness characterized by acute onset and constitutional
symptoms followed by a brief remission and a recurrence of fever, hepatitis,
albuminuria, and symptoms and, in some cases, renal failure, shock, and general-
ized hemorrhages
Laboratory criteria for diagnosis
• Fourfold or greater rise in yellow fever antibody titer with no history of recent
yellow fever immunization, and cross-reactions to other flaviviruses ruled out, or
• Demonstration of yellow fever virus, antigen, or genome in tissue, blood, or
other body fluid
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Case classification
Probable: a clinically compatible illness with supportive serology (stable elevated
antibody titer to yellow fever virus, e.g., ≥32 by complement fixation, ≥256 by
immunofluorescence assay,  ≥320 by hemagglutination inhibition, ≥160 by neutrali-
zation, or a positive serologic result by IgM-capture enzyme immunoassay.
Cross-reactive serologic reactions to other flaviviruses must be ruled out, and there
must be no history of yellow fever immunization.)
Confirmed: a clinically compatible illness that is laboratory confirmed
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